医药代表从业新规征求意见:医药代表不得承担药品销售任务

2017-12-28 陈聪 新华网

国家食品药品监督管理总局和国家卫生计生委日前发布《医药代表登记备案管理办法(试行)(征求意见稿)》,向社会公开征求意见。意见稿提出,医药代表不得承担药品销售任务,不得参与统计医生个人开具的药品处方数量,不得直接销售实物药品,不得收款和处理购销票据,不得进行商业贿赂。

国家食品药品监督管理总局和国家卫生计生委日前发布《医药代表登记备案管理办法(试行)(征求意见稿)》,向社会公开征求意见。意见稿提出,医药代表不得承担药品销售任务,不得参与统计医生个人开具的药品处方数量,不得直接销售实物药品,不得收款和处理购销票据,不得进行商业贿赂。

意见稿提出,医药代表不得误导医生使用药品,不得夸大或误导疗效,不得隐匿药品不良反应。

根据意见稿,医药代表的姓名、性别、照片、身份证号等信息需在登记备案平台备案。药品生产企业是登记备案主体,应当对其聘用或授权的医药代表在统一的平台上进行登记备案。医药代表登记备案平台由食药监总局指定。

据了解,医药代表是指代表药品上市许可持有人(持有药品批准文号的企业)在中华人民共和国境内从事药品信息传递、沟通、反馈的专业人员。进口药品总代理商可以代理境外药品上市许可持有人负责医药代表的登记备案管理工作。药品销售人员不属于医药代表。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1950640, encodeId=17a2195064012, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jul 21 17:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666677, encodeId=11c416666e733, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Feb 06 21:50:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687297, encodeId=0b1f168e2971d, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Feb 09 03:50:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949910, encodeId=6703194991029, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jan 13 04:50:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409260, encodeId=f21e140926006, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443589, encodeId=7d11144358912, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574339, encodeId=141415e433954, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273282, encodeId=bb6a2e328255, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Dec 28 19:48:47 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1950640, encodeId=17a2195064012, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jul 21 17:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666677, encodeId=11c416666e733, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Feb 06 21:50:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687297, encodeId=0b1f168e2971d, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Feb 09 03:50:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949910, encodeId=6703194991029, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jan 13 04:50:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409260, encodeId=f21e140926006, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443589, encodeId=7d11144358912, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574339, encodeId=141415e433954, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273282, encodeId=bb6a2e328255, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Dec 28 19:48:47 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2018-02-06 fengyqf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1950640, encodeId=17a2195064012, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jul 21 17:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666677, encodeId=11c416666e733, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Feb 06 21:50:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687297, encodeId=0b1f168e2971d, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Feb 09 03:50:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949910, encodeId=6703194991029, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jan 13 04:50:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409260, encodeId=f21e140926006, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443589, encodeId=7d11144358912, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574339, encodeId=141415e433954, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273282, encodeId=bb6a2e328255, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Dec 28 19:48:47 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1950640, encodeId=17a2195064012, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jul 21 17:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666677, encodeId=11c416666e733, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Feb 06 21:50:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687297, encodeId=0b1f168e2971d, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Feb 09 03:50:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949910, encodeId=6703194991029, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jan 13 04:50:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409260, encodeId=f21e140926006, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443589, encodeId=7d11144358912, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574339, encodeId=141415e433954, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273282, encodeId=bb6a2e328255, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Dec 28 19:48:47 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1950640, encodeId=17a2195064012, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jul 21 17:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666677, encodeId=11c416666e733, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Feb 06 21:50:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687297, encodeId=0b1f168e2971d, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Feb 09 03:50:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949910, encodeId=6703194991029, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jan 13 04:50:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409260, encodeId=f21e140926006, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443589, encodeId=7d11144358912, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574339, encodeId=141415e433954, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273282, encodeId=bb6a2e328255, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Dec 28 19:48:47 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2017-12-30 cathymary
  6. [GetPortalCommentsPageByObjectIdResponse(id=1950640, encodeId=17a2195064012, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jul 21 17:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666677, encodeId=11c416666e733, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Feb 06 21:50:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687297, encodeId=0b1f168e2971d, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Feb 09 03:50:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949910, encodeId=6703194991029, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jan 13 04:50:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409260, encodeId=f21e140926006, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443589, encodeId=7d11144358912, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574339, encodeId=141415e433954, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273282, encodeId=bb6a2e328255, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Dec 28 19:48:47 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1950640, encodeId=17a2195064012, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jul 21 17:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666677, encodeId=11c416666e733, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Feb 06 21:50:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687297, encodeId=0b1f168e2971d, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Feb 09 03:50:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949910, encodeId=6703194991029, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jan 13 04:50:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409260, encodeId=f21e140926006, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443589, encodeId=7d11144358912, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574339, encodeId=141415e433954, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273282, encodeId=bb6a2e328255, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Dec 28 19:48:47 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2017-12-30 xsm923
  8. [GetPortalCommentsPageByObjectIdResponse(id=1950640, encodeId=17a2195064012, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jul 21 17:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666677, encodeId=11c416666e733, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Feb 06 21:50:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687297, encodeId=0b1f168e2971d, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Feb 09 03:50:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949910, encodeId=6703194991029, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jan 13 04:50:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409260, encodeId=f21e140926006, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443589, encodeId=7d11144358912, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574339, encodeId=141415e433954, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Sat Dec 30 09:50:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273282, encodeId=bb6a2e328255, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Dec 28 19:48:47 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2017-12-28 131****1460

    学习了受益匪浅

    0

相关资讯

发改委发文,医药人睡不着了!

医用耗材加成要取消!有人欢喜有人愁,医院愁、医药人也愁!医院捂心肝微微冷笑,吓得医药人如钢箭穿身,剧痛。 ▍发改委:医用耗材加成要取消 11月10日,国家发改委发布《关于全面深化价格机制改革的意见》。顾名思义,这个文件说的是钱的事。听闻发改委要“进一步取消医用耗材加成”,特向医药人禀报。在文件第四部分的“加快完善公用事业和公共服务价格机制”中,发改委提出要巩固取消药品加成成果,

国发新规发布 如何看药代“不得卖药”?

  8日,中办、国办发布了医药行业纲领性文件《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》,较2015年8月18日国发44号文《国务院关于改革药品医疗器械审评审批制度的意见》,其中增加了对医药代表的要求,也引起了众多小伙伴们的关注,一些小伙伴们后台留言询问大咪对此的解读,这里统一和大家分享下个人的看法:

西安:医药代表要登记备案

近日,业内又流出有关医药代表备案的通知,这是一份来源于西安市食药监局的红头文件,文件对医药代表登记备案和信息公开的有关事项作了明确说明。

只有生产企业才能为医药代表备案,CSO和经销商路在何方?

除药品生产企业外,谁还有资格为医药代表备案?这个关系百万药代命运的问题,国家食药监总局局长毕井泉日前给出明确答案:“医药代表是上市许可持有人派出的工作人员,承担着药品学术推广、向医生介绍药品知识的重要责任。”

国家版药代备案制征求意见 医药代表行为法制化

果然又是周五见!CFDA真是拼了,在这个时候,医药代表登记备案管理办法(征求意见稿)正式出炉……2017年12月22日晚7时许,国家食品药品监督管理总局以及国家卫计委同时在官方网站挂出消息,就“医药代表登记备案管理办法”(以下简称“办法”)正式面向社会公开征求意见,共计五大章节二十条内容。备受关注的医药代表登记备案管理办法终于“千呼万唤始出来”。可以说,从年初至岁末,自2017年重磅政策文件《

备案制下的百万药代还有这些新出路(上篇)

从今年2月9日国务院办公厅印发《关于进一步改革完善药品生产流通使用政策的若干意见》中首先从国家层面提出要求医药代表只能从事学术推广、技术咨询等活动,不得承担药品销售任务,其失信行为记入个人信用记录的代表备案制,到上海出台的代表备案中的“三定一有”及安徽相继出台医药代表备案细则,再到十九大明确提出全面以药养医,《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》中再次重申禁止医药代表承担药品销售任